戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 tilation, and receipt of benzodiazepines and anticholinergics.
2 ojections, as produced by septal infusion of anticholinergics.
3 nd treatment centred on early institution of anticholinergics.
4 nasal decongestant, saline douches and nasal anticholinergics.
5 rected] of the patients treated with inhaled anticholinergics (2.1%) and 108 [corrected] of the contr
6 atients (1.9%) [corrected] receiving inhaled anticholinergics and 83 of 6661 [corrected] patients (1.
7 ee classes of bronchodilators-beta agonists, anticholinergics, and theophylline-are available and can
8                                      Inhaled anticholinergics are associated with a significantly inc
9    These studies provided good evidence that anticholinergics are effective at improving both urodyna
10  consists of medical therapy, primarily with anticholinergics as well as behavioral therapy to modify
11 response to botulinum toxin is not adequate, anticholinergics, benzodiazepines, baclofen and other me
12 dase type B inhibitors [MAOBIs], amantadine, anticholinergics, beta-blockers, or dopamine agonists) m
13               Current COPD therapy involving anticholinergics, beta2-adrenoceptor agonists and/or cor
14 rent autonomic failure; dramatic response to anticholinergics; early or atypical L-dopa-induced dyski
15  evidence on the effectiveness and safety of anticholinergics for male lower urinary tract symptoms.
16 esting in children; enuresis topics included anticholinergics for treating monosyptomatic enuresis re
17 nts, antidepressants, fiber, probiotics, and anticholinergics have not been adequately studied.
18        Safety data from larger studies using anticholinergics in patients with overactive bladders su
19 etylcholinesterase inhibitors and muscarinic anticholinergics in these patients.
20 nd new or broadened indications for existing anticholinergics, in treating the overactive bladder in
21 QSAR) study is presented for quaternary soft anticholinergics including two distinctly different clas
22                                      Inhaled anticholinergics (ipratropium bromide or tiotropium brom
23 ose with detrusor overactivity refractory to anticholinergics, is, however, evidenced increasingly.
24 lly evaluation of various inhaled therapies (anticholinergics, long-acting beta-agonists, and cortico
25 ation inhaled therapies (long-acting inhaled anticholinergics, long-acting inhaled beta-agonists, or
26 acting anticholinergics (n = 7), long-acting anticholinergics (n = 10), long-acting beta2-agonists (n
27 CTs examined inhaled therapies: short-acting anticholinergics (n = 7), long-acting anticholinergics (
28 pain control, minimizing benzodiazepines and anticholinergics, normalizing the sleep-wake cycle, prov
29 tention, because of the inhibitory effect of anticholinergics on bladder contraction in the presence
30   Pharmacologic interventions include use of anticholinergics or antipsychotic medications for dement
31 monotherapy using either long-acting inhaled anticholinergics or long-acting inhaled beta-agonists fo
32 g inhaled beta-agonists, long-acting inhaled anticholinergics, or inhaled corticosteroids.
33 T3 receptor antagonists, antihistamines, and anticholinergics reduce the incidence of PONV, whereas m
34                                              Anticholinergics remain the first line in pharmacotherap
35 components of the primary end point, inhaled anticholinergics significantly increased the risk of MI
36                                      Inhaled anticholinergics such as ipratropium bromide (IB), when
37  therapy with inhaled beta-agonists, inhaled anticholinergics, systemic corticosteroids, and intraven
38 MI, or stroke (2.9% of patients treated with anticholinergics vs 1.8% of the control patients; RR, 1.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。